Payment overview · 2025
General Payments
$146.55
3 reported records · 2 companies
Healthcare provider profile · identity verified
Jeffrey D Davis, DO
Allopathic & Osteopathic Physicians|Family Medicine · MEMPHIS, MO · NPI 1679558589
Verified facts
What the public records show
CMS Open Payments records show Jeffrey D Davis, DO received $146.55 in general payments during 2025 across 3 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 89.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $131.33 | 89.6% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $15.22 | 10.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.55 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $131.33 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 534 | 64 |
| Potassium Chloride | Potassium Chloride | 465 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 39 |
| Eliquis | Apixaban | 303 | 27 |
| Tramadol Hcl | Tramadol Hcl | 291 | 61 |
| Atorvastatin Calcium | Atorvastatin Calcium | 275 | 40 |
| Gabapentin | Gabapentin | 267 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | 26 |
| Lisinopril | Lisinopril | 195 | 27 |
| Buspirone Hcl | Buspirone Hcl | 175 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 175 | 22 |
| Sertraline Hcl | Sertraline Hcl | 164 | 23 |
| Losartan Potassium | Losartan Potassium | 163 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 148 | 18 |
| Famotidine | Famotidine | 142 | 19 |
| Donepezil Hcl | Donepezil Hcl | 141 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 13 |
| Carvedilol | Carvedilol | 127 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 124 | 13 |
| Memantine Hcl | Memantine Hcl | 124 | 18 |
| Lorazepam | Lorazepam | 122 | 26 |
| Spironolactone | Spironolactone | 121 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 16 |
| Omeprazole | Omeprazole | 119 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 116 | 17 |
| Allopurinol | Allopurinol | 113 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 11 |
| Simvastatin | Simvastatin | 102 | suppressed |
| Mirtazapine | Mirtazapine | 97 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 92 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | suppressed |
| Xarelto | Rivaroxaban | 81 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 11 |
| Risperidone | Risperidone | 79 | suppressed |
| Prednisone | Prednisone | 76 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 18 |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,sf 0.5ml | 67 | suppressed |
| Finasteride | Finasteride | 66 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | suppressed |
| Irbesartan | Irbesartan | 65 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 64 | suppressed |
| Trulicity | Dulaglutide | 62 | suppressed |
| Myrbetriq | Mirabegron | 61 | suppressed |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 56 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Latanoprost | Latanoprost | 52 | suppressed |
| Metformin Hcl | Metformin Hcl | 52 | 11 |
| Cephalexin | Cephalexin | 51 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | suppressed |
| Ondansetron Odt | Ondansetron | 50 | 18 |
| Metformin Hcl Er | Metformin Hcl | 49 | suppressed |
| Torsemide | Torsemide | 49 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 47 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 16 |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 43 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Cefdinir | Cefdinir | 41 | 31 |
| Fluconazole | Fluconazole | 40 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 12 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 13 |
| Multaq | Dronedarone Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 21 |
| Novolog | Insulin Aspart | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Levemir | Insulin Detemir | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Tresiba | Insulin Degludec | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Nystatin | Nystatin | 23 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Admelog | Insulin Lispro | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Zafirlukast | Zafirlukast | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Thyroid | Thyroid,pork | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.55 · 3 records | Otsuka America Pharmaceutical, Inc. | Prolastin-C Liquid, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error